Cheong W K, Thirumoorthy T
Middle Road Hospital, Singapore.
Ann Acad Med Singap. 1987 Oct;16(4):631-5.
Acyclovir is a highly potent inhibitor of herpes simplex virus types 1 and 2 and varicella zoster virus, and has a remarkably low toxicity for normal host cells. It is now available as an ophthalmic ointment, skin cream and oral and intravenous formulations. Clinical trials in the past few years have shown acyclovir to be clinically useful in the therapy of certain aspects of genital herpes infection. Acyclovir has also been shown to be useful in herpes zoster, especially in immunocompromised patients. A retrospective study on the use of acyclovir was carried out on 14 patients with first episode genital herpes and 3 patients with eczema herpeticum. In patients with genital herpes, relief of symptoms was experienced within three days of treatment and lesions showed healing within five to seven days of treatment. Two out of the three patients with eczema herpeticum showed dramatic response to acyclovir; the lesions healed completely after six days of treatment.
阿昔洛韦是单纯疱疹病毒1型和2型以及水痘带状疱疹病毒的高效抑制剂，对正常宿主细胞的毒性极低。它现在有眼膏、乳膏以及口服和静脉制剂。过去几年的临床试验表明，阿昔洛韦在治疗生殖器疱疹感染的某些方面具有临床实用性。阿昔洛韦也已被证明对带状疱疹有效，尤其是对免疫功能低下的患者。对14例初发性生殖器疱疹患者和3例疱疹性湿疹患者进行了一项关于阿昔洛韦使用情况的回顾性研究。在生殖器疱疹患者中，治疗三天内症状得到缓解，治疗五至七天内皮损愈合。3例疱疹性湿疹患者中有2例对阿昔洛韦有显著反应；治疗六天后皮损完全愈合。
